June 13, 2008 -- GlaxoSmithKline today announced the approval of Requip(R) XL(TM) (ropinirole extended-release tablets) in the U.S. for the treatment of the signs and symptoms of idiopathic Parkinson's disease. Requip XL is the first and only oral once-daily non-ergot dopamine agonist indicated for Parkinson's disease. The product should be available in pharmacies in mid-July 2008.
The details can be read here.
No comments:
Post a Comment